A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments
Patients showed a clear preference for treatment efficacy (PFS/OS and ORR). This study confirmed patients' valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.
Authors
- Joseph Mıkhael (ORCID: https://orcid.org/0000-0001-9670-2864)
- Saurabh Patel (ORCID: https://orcid.org/0000-0001-9472-0188)
- Beth Faiman (ORCID: https://orcid.org/0000-0002-8153-0438)
- Agne Paner-Straseviciute
- Xinke Zhang (ORCID: https://orcid.org/0009-0008-9564-9369)
- Julie Laurent (ORCID: https://orcid.org/0000-0002-1705-7631)
- Hoa H. Le (ORCID: https://orcid.org/0000-0001-6755-1331)
Institutions
- Translational Genomics Research Institute (US)
- Cleveland Clinic (US)
- Johnson & Johnson (United States) (US)
- Dignity Health (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fonc.2025.1628121
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00